The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders : a randomised controlled study. / Vinberg, Maj; Miskowiak, Kamilla; Hoejman, Pernille; Pedersen, Maria; Kessing, Lars Vedel.

In: PLOS ONE, 2015, p. 1-16.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Vinberg, M, Miskowiak, K, Hoejman, P, Pedersen, M & Kessing, LV 2015, 'The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study', PLOS ONE, pp. 1-16. https://doi.org/10.1371/journal.pone.0127629

APA

Vinberg, M., Miskowiak, K., Hoejman, P., Pedersen, M., & Kessing, L. V. (2015). The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study. PLOS ONE, 1-16. [e0127629]. https://doi.org/10.1371/journal.pone.0127629

Vancouver

Vinberg M, Miskowiak K, Hoejman P, Pedersen M, Kessing LV. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study. PLOS ONE. 2015;1-16. e0127629. https://doi.org/10.1371/journal.pone.0127629

Author

Vinberg, Maj ; Miskowiak, Kamilla ; Hoejman, Pernille ; Pedersen, Maria ; Kessing, Lars Vedel. / The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders : a randomised controlled study. In: PLOS ONE. 2015 ; pp. 1-16.

Bibtex

@article{32246aac37e74551b229947f4b55aa65,
title = "The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study",
abstract = "UNLABELLED: The study aims to investigate the effect of repeated infusions of recombinant erythropoietin (EPO) on plasma brain derived neurotrophic factor (BDNF) levels in patients with affective disorders. In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression (TRD) (Hamilton Depression Rating Scale-17 items (HDRS-17) score >17) (study 1) and 43 patients with bipolar disorder (BD) in partial remission (HDRS-17 and Young Mania Rating Scale (YMRS) ≤ 14) (study 2). In both studies, patients were randomised to receive eight weekly EPO (Eprex; 40,000 IU) or saline (0.9{\%} NaCl) infusions in a double-blind, placebo-controlled, parallel--group design. Plasma BDNF levels were measured at baseline and at weeks 5, 9 and at follow up, week 14. In contrast with our hypothesis, EPO down regulated plasma BDNF levels in patients with TRD (mean reduction at week 9 (95{\%} CI): EPO 10.94 ng/l (4.51-21.41 ng/l); mean increase at week 9: Saline 0.52 ng/l, p=0.04 (-5.88-4.48 ng/l) p=0.04, partial ŋ2=0.12). No significant effects were found on BDNF levels in partially remitted patients with BD (p=0.35). The present effects of EPO on BDNF levels in patients with TRD point to a role of neurotrophic factors in the potential effects of EPO seen in TRD and BD. The neurobiological mechanisms underlying these effects and the interaction between EPO and peripheral levels on BDNF need to be further elucidated in human studies including a broad range of biomarkers.TRIAL REGISTRATION: ClinicalTrials.gov: NCT00916552.",
author = "Maj Vinberg and Kamilla Miskowiak and Pernille Hoejman and Maria Pedersen and Kessing, {Lars Vedel}",
year = "2015",
doi = "10.1371/journal.pone.0127629",
language = "English",
pages = "1--16",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",

}

RIS

TY - JOUR

T1 - The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders

T2 - a randomised controlled study

AU - Vinberg, Maj

AU - Miskowiak, Kamilla

AU - Hoejman, Pernille

AU - Pedersen, Maria

AU - Kessing, Lars Vedel

PY - 2015

Y1 - 2015

N2 - UNLABELLED: The study aims to investigate the effect of repeated infusions of recombinant erythropoietin (EPO) on plasma brain derived neurotrophic factor (BDNF) levels in patients with affective disorders. In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression (TRD) (Hamilton Depression Rating Scale-17 items (HDRS-17) score >17) (study 1) and 43 patients with bipolar disorder (BD) in partial remission (HDRS-17 and Young Mania Rating Scale (YMRS) ≤ 14) (study 2). In both studies, patients were randomised to receive eight weekly EPO (Eprex; 40,000 IU) or saline (0.9% NaCl) infusions in a double-blind, placebo-controlled, parallel--group design. Plasma BDNF levels were measured at baseline and at weeks 5, 9 and at follow up, week 14. In contrast with our hypothesis, EPO down regulated plasma BDNF levels in patients with TRD (mean reduction at week 9 (95% CI): EPO 10.94 ng/l (4.51-21.41 ng/l); mean increase at week 9: Saline 0.52 ng/l, p=0.04 (-5.88-4.48 ng/l) p=0.04, partial ŋ2=0.12). No significant effects were found on BDNF levels in partially remitted patients with BD (p=0.35). The present effects of EPO on BDNF levels in patients with TRD point to a role of neurotrophic factors in the potential effects of EPO seen in TRD and BD. The neurobiological mechanisms underlying these effects and the interaction between EPO and peripheral levels on BDNF need to be further elucidated in human studies including a broad range of biomarkers.TRIAL REGISTRATION: ClinicalTrials.gov: NCT00916552.

AB - UNLABELLED: The study aims to investigate the effect of repeated infusions of recombinant erythropoietin (EPO) on plasma brain derived neurotrophic factor (BDNF) levels in patients with affective disorders. In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression (TRD) (Hamilton Depression Rating Scale-17 items (HDRS-17) score >17) (study 1) and 43 patients with bipolar disorder (BD) in partial remission (HDRS-17 and Young Mania Rating Scale (YMRS) ≤ 14) (study 2). In both studies, patients were randomised to receive eight weekly EPO (Eprex; 40,000 IU) or saline (0.9% NaCl) infusions in a double-blind, placebo-controlled, parallel--group design. Plasma BDNF levels were measured at baseline and at weeks 5, 9 and at follow up, week 14. In contrast with our hypothesis, EPO down regulated plasma BDNF levels in patients with TRD (mean reduction at week 9 (95% CI): EPO 10.94 ng/l (4.51-21.41 ng/l); mean increase at week 9: Saline 0.52 ng/l, p=0.04 (-5.88-4.48 ng/l) p=0.04, partial ŋ2=0.12). No significant effects were found on BDNF levels in partially remitted patients with BD (p=0.35). The present effects of EPO on BDNF levels in patients with TRD point to a role of neurotrophic factors in the potential effects of EPO seen in TRD and BD. The neurobiological mechanisms underlying these effects and the interaction between EPO and peripheral levels on BDNF need to be further elucidated in human studies including a broad range of biomarkers.TRIAL REGISTRATION: ClinicalTrials.gov: NCT00916552.

U2 - 10.1371/journal.pone.0127629

DO - 10.1371/journal.pone.0127629

M3 - Journal article

C2 - 26011424

SP - 1

EP - 16

JO - P L o S One

JF - P L o S One

SN - 1932-6203

M1 - e0127629

ER -

ID: 160478231